CellSeed

CellSeed P/TBV

The Price to Tangible Book Value (P/TBV) of CellSeed (7776.T) as of Oct 27, 2026 is 9.18. In the previous year, Price to Tangible Book Value (P/TBV) was 5.38 — a change of 70.55% (higher).

P/TBV

9.18

YoY

70.55%

Last updated:

Price to Tangible Book Value (P/TBV) of CellSeed is 2025 9.18 . Price to Tangible Book Value (P/TBV) of CellSeed was 2024 5.38 . It decreases by 70.55% higher compared to the previous year.

The CellSeed P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
8.25 JPY
Jan 1, 2019
8.66 JPY
Jan 1, 2020
7.63 JPY
Jan 1, 2021
11.15 JPY
Jan 1, 2022
9.88 JPY
Jan 1, 2023
5.38 JPY
Jan 1, 2024
5.38 JPY
Jan 1, 2025
9.18 JPY
The CellSeed P/TBV history
YEARP/TBVYoY
9.18+70.55%
5.38+0.07%
5.38-45.57%
9.88-11.35%
11.15+46.12%
7.63-11.87%
8.66+4.91%
8.25-10.87%
9.26-7.43%
10.00+105.22%
4.87+17.90%
4.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Price to Tangible Book Value (P/TBV) of CellSeed is 9.18 in 2025.

Price to Tangible Book Value (P/TBV) of CellSeed changed from 5.38 to 9.18, representing a 70.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) CellSeed since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s CellSeed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CellSeed

All Key Metrics — CellSeed